The company has determined that additional investments of time and resources in these programs are not appropriate given the other opportunities in its product development pipeline.
The terminated programs were evaluating three synthetic endocannabinoid compounds, KAL436, KAL439 and KAL671, in bone fracture healing, and osteogenesis imperfecta and osteoporosis.
In connection with the termination of these programs, Kalytera has terminated its License Agreement with Yissum Research Development company of the Hebrew University of Jerusalem, Ltd., under which Kalytera had licensed rights to KAL436, KAL439 and KAL671.
Kalytera seeks to establish a position in the development of novel cannabinoid medicines for a range of important unmet medical needs, with an initial focus on graft versus host disease and the treatment of acute and chronic pain.
Micreos passes US FDA approval for PhageGuard-E to combat E. Coli O157
Valeo Pharma signs strategic agreement with Besins Healthcare
Roivant Sciences launches Respivant Sciences
US FDA grants rare paediatric disease designation to Cellectar Biosciences' CLR 131
Janssen submits erdafitinib's NDA with the US FDA for the treatment of metastatic urothelial cancer
Positive Cytisine Data Published in International Journal of Drug Policy
FDA Grants Lin BioScience Rare Pediatric Disease Status for LBS-008 to Treat Stargardt Disease